Approved Ligands

Application：Naltrexone is an opioid antagonist shown to reduce the occurrence of addictive behaviours such as eating, smoking and drinking excessively. in addition to curbing drug use， it has recently been used in flavor avoidance studies.

Application：Naltrexone is an opioid antagonist shown to reduce the occurrence of addictive behaviours such as eating, smoking and drinking excessively. in addition to curbing drug use， it has recently been used in flavor avoidance studies.

Application：Naltrexone is an opioid antagonist shown to reduce the occurrence of addictive behaviours such as eating, smoking and drinking excessively. in addition to curbing drug use， it has recently been used in flavor avoidance studies.

Application：Naltrexone is an opioid antagonist shown to reduce the occurrence of addictive behaviours such as eating, smoking and drinking excessively. in addition to curbing drug use， it has recently been used in flavor avoidance studies.

Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM: weakly inhibits KDR and Src, no significant inhibition to Akt, CDK1/2/4, IKK-2, MK-2, PDK1, c-Raf and c-Met. Phase 3.A potent and selective inhibitor of

Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM: weakly inhibits KDR and Src, no significant inhibition to Akt, CDK1/2/4, IKK-2, MK-2, PDK1, c-Raf and c-Met. Phase 3.A potent and selective inhibitor of

Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM: weakly inhibits KDR and Src, no significant inhibition to Akt, CDK1/2/4, IKK-2, MK-2, PDK1, c-Raf and c-Met. Phase 3.A potent and selective inhibitor of

Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM: weakly inhibits KDR and Src, no significant inhibition to Akt, CDK1/2/4, IKK-2, MK-2, PDK1, c-Raf and c-Met. Phase 3.A potent and selective inhibitor of

Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM.A rationally designed c-Abl and Bcr-Abl kinase inhibitor.

Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM.A rationally designed c-Abl and Bcr-Abl kinase inhibitor.

Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM.A rationally designed c-Abl and Bcr-Abl kinase inhibitor.

Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM.A rationally designed c-Abl and Bcr-Abl kinase inhibitor.